Near real-time data on the human neutralizing antibody landscape to influenza virus in summer of 2026 shows antigenic advance of H3N2 subclade K region D mutants and H1N1 D.3.1.1 Sa mutants
This paper presents near real-time neutralization data from summer 2026, revealing that emerging H3N2 subclade K region D and H1N1 D.3.1.1 Sa mutants exhibit reduced susceptibility to human antibodies, thereby providing critical evidence to inform influenza vaccine strain selection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Every year, the world faces a familiar challenge: deciding which version of the influenza virus to target with the upcoming flu vaccine. Because the virus changes its appearance constantly, the protection offered by last year's shot may not fit this year's threat. Scientists must look into the future, predicting which viral strains will dominate months before the vaccine is even manufactured. This prediction relies on understanding how the human immune system, shaped by past infections and vaccinations, recognizes and fights these shifting viral shapes. The key to this defense lies in antibodies, the proteins our bodies produce to lock onto the virus and stop it from infecting cells. When the virus changes its shape just enough to slip past these antibodies, it can spread more easily, rendering the current vaccine less effective.
In the summer of 2026, a team of researchers took a close look at this moving target. They gathered blood samples from 355 people across the United States and Australia, representing a wide range of ages and vaccination histories. Using a high-speed laboratory technique that can test thousands of interactions at once, they measured how well these human antibodies could neutralize 148 different strains of the flu virus circulating at that time. The goal was to see if the virus had evolved new disguises that would allow it to escape the immune system's defenses. Their work revealed that the two main types of seasonal flu, H3N2 and H1N1, had indeed developed new variants that were harder for human antibodies to catch. Specifically, they found that new versions of the H3N2 virus had acquired mutations in a specific area of their surface protein that made them significantly more difficult to neutralize. Similarly, the H1N1 virus had evolved a new variant with changes that reduced its vulnerability to antibodies, particularly in a group of people who were teenagers or young adults.
The researchers focused on the hemagglutinin protein, the main surface feature of the flu virus that antibodies try to grab onto. They constructed a library of viruses representing the diversity of flu strains seen in late 2025 and early 2026. This library included 82 strains of H3N2 and 66 strains of H1N1, covering the most common variants and the newest emerging ones. They then mixed these viruses with the blood serum from their 355 human donors to see how effectively the antibodies in the blood could stop the viruses from infecting cells. The results showed a clear pattern of the virus evolving to escape immunity. For the H3N2 virus, the most successful new strains belonged to a group called subclade K. While the original subclade K was already somewhat different from older strains, new descendants of this group had picked up additional changes in a region of the virus known as antigenic region D. These specific changes, occurring at positions 222 and 223 on the virus's surface, made the virus much harder for human antibodies to neutralize. In many cases, the antibodies that could still catch the older versions of the virus failed to stop these new mutants.
The situation was similar for the H1N1 virus, which had shifted from the subclade D.3.1, included in the 2026 vaccine, to a new subclade called D.3.1.1. This new variant carried mutations that reduced how well it was neutralized by human blood. One mutation in particular, located at position 155 in a region called antigenic region Sa, stood out. This change, known as G155E, made the virus significantly harder to neutralize for a specific group of people: teenagers and young adults. These individuals, who were likely first exposed to flu during or shortly after the 2009 pandemic, had immune systems that reacted strongly to this new mutation, often failing to neutralize the virus effectively. Older adults, whose immune systems were shaped by flu strains from before 2009, were less affected by this specific change. This finding highlights how the history of a person's exposure to the flu shapes their ability to fight off new variants.
The study also examined what happens when people receive the flu vaccine. The researchers tested blood samples from Australian volunteers before and after they received the 2026 Southern Hemisphere flu shot. As expected, the vaccine boosted the levels of antibodies against all the flu strains tested. However, the boost was not selective; the vaccine did not produce a significantly stronger response against the new, mutated strains compared to the older ones that matched the vaccine. Instead, the pattern of protection after vaccination largely mirrored the pattern before vaccination. People who had high levels of antibodies against the new variants before the shot saw a similar increase in protection after the shot as those who had lower levels. This suggests that the current vaccine, while it increases overall protection, does not fully overcome the virus's ability to evade the immune system through these new mutations.
Despite these findings, the researchers noted that predicting exactly which strain will dominate the next flu season remains difficult. While the new variants with reduced neutralization are spreading, it is not yet certain which specific combination of mutations will become the most successful in the coming year. The virus continues to evolve, and other factors, such as how easily the virus spreads between people, also play a role in its success. The study provides a crucial snapshot of the immune landscape at a specific moment in time, offering data that can help inform the decision of which virus to include in the next vaccine. By mapping out exactly how human antibodies interact with the latest viral shapes, the researchers have provided a clearer picture of the ongoing battle between the flu virus and the human immune system, a battle that requires constant vigilance and adaptation.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.